Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: tsuneizumi m. Breast Cancer. 2024 Jul;31(4):621-632. doi: 10.1007/s12282-024-01575-5. Epub 2024 Apr 20. Breast Cancer. 2024. PMID: 38642245 Free PMC article.
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H. Niikura N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2014 Aug;147(1):103-12. doi: 10.1007/s10549-014-3090-8. Epub 2014 Aug 9. Breast Cancer Res Treat. 2014. PMID: 25106661
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H. Hayashi N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21. Breast Cancer Res Treat. 2015. PMID: 25528021
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H. Niikura N, et al. Among authors: tsuneizumi m. Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11. Breast Cancer Res Treat. 2018. PMID: 28895005 Clinical Trial.
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.
Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H. Ogiya R, et al. Among authors: tsuneizumi m. Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262592 Free PMC article.
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H. Toyama T, et al. Among authors: tsuneizumi m. Breast Cancer. 2018 Nov;25(6):729-735. doi: 10.1007/s12282-018-0879-z. Epub 2018 Jun 8. Breast Cancer. 2018. PMID: 29948956 Clinical Trial.
40 results